Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia?-Reference-Cited by-同舟云学术

Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia?

Published:2024-09-10 Issue: Volume: Page:
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Stutterheim Janine^ORCID,van der Waarden Rachella,de Groot-Kruseman Hester A.,Sonneveld Edwin,de Haas Valérie^ORCID,Dandis Rana,van der Schoot C. Ellen,van der Velden Vincent H. J.^ORCID,Pieters Rob^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41375-024-02386-5.pdf

Reference15 articles.

1. Van Dongen JJM, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352:1731–8.

2. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008;22:771–82.

3. Pieters R, De Groot-Kruseman H, Van Der Velden V, Fiocco M, Van Den Berg H, De Bont E, et al. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: Study ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol. 2016;34:2591–601.

4. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grümayer R, Möricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFMALL 2000 study. Blood. 2010;115:3206–14.

5. Schrappe M, Bleckmann K, Zimmermann M, Biondi A, Möricke A, Locatelli F, et al. Reduced-intensity delayed intensification in standard-risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: results of an international randomized trial (AIEOP-BFM ALL 2000). J Clin Oncol. 2018;36:244–53.